Japan’s Health Ministry on Monday approved the use of Novavax’s protein-based COVID-19 vaccine, making it the fourth vaccine option available for people aged 18 and above.
Japan has contracted to buy 150 million doses of the vaccine, which will be manufactured domestically by Takeda Pharmaceutical Co. Takeda first applied for approval in December last year, local media Kyodo News reported.
